Karyopharm Therapeutics Inc. (KPTI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Karyopharm Therapeutics Inc. (KPTI) closed at USD 0.35 on 2026-10-15, a change of -94.2 % over the past year, with a market capitalization of USD 8.85M.

Karyopharm Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Karyopharm Therapeutics Inc. key figures

Previous close

USD 0.35 (2026-10-15)

1-year change

-94.2 %

Market cap

USD 8.85M

Enterprise value

USD 272.27M

P/E ratio (trailing)

-0.03

P/E ratio (forward)

-0.14

EPS (trailing)

-14.33

EPS (forward)

-2.82

PEG ratio

n/a

Price to book

-0.03

Revenue growth

-11.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.17

Employees

228

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Karyopharm Therapeutics Inc. and compare it with other stocks.